Literature DB >> 32847996

Race-driven survival differential in women diagnosed with endometrial cancers in the USA.

Zachary D Horne1, Solomiya R Teterichko2, Scott M Glaser3, Rodney E Wegner4, Shaakir Hasan5, Sarah M Crafton6, Eirwen M Miller6, Thomas C Krivak6, Akila Viswanathan7, Alexander B Olawaiye8, Paniti Sukumvanich8, Sushil Beriwal9.   

Abstract

OBJECTIVE: African American women are increasingly being diagnosed with advanced and type II histology endometrial cancers. Outcomes have been observed to be worse in African American women, but whether or not race itself is a factor is unclear. We sought to evaluate the rates of diagnosis and outcomes on a stage-by-stage basis with respect to race using a large national cancer registry database.
METHODS: The National Cancer Data Base was searched for patients with surgically staged non-metastatic endometrial cancer between 2004 and 2015. Women were excluded if surgical stage/histology was unknown, there was no follow-up, or no information on subsequent treatment. Pairwise comparison was used to determine temporal trends and Cox hazards tests with Bonferroni correction were used to determine overall survival.
RESULTS: A total of 286 920 women were diagnosed with endometrial cancer and met the criteria for analysis. Median follow-up was 51 months (IQR 25.7-85.3). In multivariable models, in women with stage I disease, African American women had a higher risk of death than Caucasian women (HR 1.262, 95% CI 1.191 to 1.338, p<0.001) and Asian/Pacific Islander women had a lower risk of death than Caucasian women (HR 0.742, 95% CI 0.689 to 0.801, p<0.001). This held for African American women with stage II type I and type II disease (HR 1.26, 95% CI 1.109 to 1.444, p<0.001 and HR 1.235, 95% CI 1.098 to 1.388, p<0.001) but not for Asian/Pacific Islander women. African American women with stage IIIA-B disease also had a higher risk of death for type I and type II disease versus Caucasian women (HR 1.221, 95% CI 1.045 to 1.422, p=0.010 and HR 1.295, 95% CI 1.155 to 1.452, p<0.001). Asian/Pacific Islander women had a lower risk of death than Caucasian women with type I disease (HR 0.783, 95% CI 0.638 to 0.960, p=0.019) and type II disease (HR 0.790, 95% CI 0.624 to 0.999, p=0.05). African American women with stage IIIC1-2 had a higher risk of death with type I disease (HR 1.343, 95% CI 1.207 to 1.494, p<0.001) and type II disease (HR 1.141, 95% CI 1.055 to 1.233, p=0.001) whereas there was no significant difference between Caucasian women and Asian/Pacific Islander women.
CONCLUSION: Race appears to play an independent role in survival from endometrial cancer in the USA, with African American women having worse survival on a stage-for-stage basis compared with Caucasian women. © IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  radiation oncology; uterine cancer

Year:  2020        PMID: 32847996     DOI: 10.1136/ijgc-2020-001560

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  4 in total

1.  Disparities in cancer-specific and overall survival in black women with endometrial cancer: A Medicare-SEER study.

Authors:  Daniel H Saris; Anna Jo Bodurtha Smith; Colleen Brensinger; Sarah H Kim; Ashley F Haggerty; Nawar Latif; Lori Cory; Robert L Giuntoli; Mark A Morgan; Lilie L Lin; Emily M Ko
Journal:  Gynecol Oncol Rep       Date:  2022-01-06

2.  Disparities in Survival and Comorbidity Burden Between Asian and Native Hawaiian and Other Pacific Islander Patients With Cancer.

Authors:  Kekoa Taparra; Vera Qu; Erqi Pollom
Journal:  JAMA Netw Open       Date:  2022-08-01

3.  Clinicopathological Characteristics and Prognosis in Endometrial Cancer With Bone Metastasis: A SEER-Based Study of 584 Women.

Authors:  Hejia Hu; Zhan Wang; Miaofeng Zhang; Feng Niu; Qunfei Yu; Ying Ren; Zhaoming Ye
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

4.  Guideline-adherent treatment, sociodemographic disparities, and cause-specific survival for endometrial carcinomas.

Authors:  Victoria E Rodriguez; Alana M W LeBrón; Jenny Chang; Robert E Bristow
Journal:  Cancer       Date:  2021-03-15       Impact factor: 6.921

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.